Premium
The case for routine use of adjuvant therapy in pancreatic cancer
Author(s) -
Kennedy Eugene P.,
Yeo Charles J.
Publication year - 2007
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.20719
Subject(s) - medicine , pancreatic cancer , adjuvant therapy , disease , immunotherapy , pancreatic ductal adenocarcinoma , adenocarcinoma , surgical resection , pancreatectomy , adjuvant , cancer , resection , oncology , general surgery , surgery , intensive care medicine
Pancreatic cancer is a devastating disease with a poor prognosis for most patients. Surgical resection remains the cornerstone of treatment, providing the only realistic hope of long‐term survival. Even with optimal surgical management, 5‐year survival averages 15% to 20% for resectable disease. Progress is being made, however. Currently, the benefits of postoperative therapy for resected pancreatic ductal adenocarcinoma appear clear, and recommendations for such therapy appear to us to be well justified. Additional benefit to patients awaits the development of new agents, molecular targeted drugs, and novel approaches such as immunotherapy. J. Surg. Oncol. 2007;95:597–603. © 2007 Wiley‐Liss, Inc.